Press Release: September 22, 2016 Ι 1:40 PM ET

VICTORIA, /CNW/ - Emerald Health Therapeutics Inc. (TSXV: EMH) ("Therapeutics") is pleased to announced that its wholly owned subsidiary, Emerald Health Botanicals Inc. ("Botanicals"), has launched its initial three cannabis oil products - THCA oil, THC oil, and THC:CBD oil.  Our cannabis oils are whole plant cannabis extracts that deliver the benefits of cannabinoids orally. Oils are easily ingested and allow for more accurate dosing without the need for inhalation. Our team of PhDs and MDs are working to further develop a range of cannabis-based products, while researching the effect of cannabis and cannabinoids on health in clinical studies.

Botanicals is proud to be the first Licensed Producer in Canada to offer THCA (Tetrahydrocannabinolic acid) oil.  THCA is the precursor to THC and has no psychotropic effects.  THCA is isolated from cannabis through a very gentle extraction process.

"We believe being able to provide our patients with cannabis oils in a form that can be properly dosed is a big step forward for Botanicals.  Oils, such as THCA, that provide the benefits of cannabis without a psychotropic effect, should be of great benefit to our patients and the medical community." stated Dr. Avtar Dhillon, Chairman of Therapeutics. 

ON BEHALF OF THE BOARD

"Dr. Bin Huang"

CEO

Emerald Health Therapeutics Inc.
Therapeutics wholly owns Botanicals, which has been granted licences under the Access to Cannabis for Medical Purposes Regulations (Canada) to cultivate and sell medical cannabis, and to produce and sell medical cannabis oils in Canada.   

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Emerald Health Therapeutics, Inc.

Image with caption: "Emerald Health Therapeutics (CNW Group/Emerald Health Therapeutics, Inc.)". Image available at: http://photos.newswire.ca/images/download/20160922_C3948_PHOTO_EN_779839.jpg

For further information: Please contact Emerald Health Therapeutics CFO, Sandy Pratt, at 250-818-9838 or invest@emerald.care.